TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Consensus PT from Analysts
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the […]
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the […]
